💊 医薬品 A-Z 🧬 標的 🛠 ツール 📚 ガイド
全医薬品 薬物分類 治療領域 副作用
ガイド 用語集 年表
比較 薬物の体内の旅 薬物ファミリー
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Temafloxacin

CHEMBL277100 Phase 4 承認済み Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
417.4 g/mol
LogP
0.6
Phase
4

Temafloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, enzymes essential for DNA replication, transcription, and repair, producing bactericidal effects against a broad spectrum of gram-positive and gram-negative organisms. It was withdrawn from the market in 1992 due to a rare but serious syndrome of hemolytic anemia, hypoglycemia, and coagulopathy (temafloxacin syndrome). Its pharmacological mechanism is similar to other fluoroquinolones but its idiosyncratic toxicity profile led to permanent market withdrawal.

分子量

417.4000 g/mol

LogP

0.60

TPSA

72.90 Ų

リピンスキーの五則

適合

作用機序

Inhibits DNA topoisomerase, preventing the relaxation of supercoiled DNA during replication and transcription. This causes DNA strand breaks and triggers apoptosis in rapidly dividing cells.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

機序

Inhibits DNA topoisomerase, preventing the relaxation of supercoiled DNA during replication and transcription. This causes DNA strand breaks and triggers apoptosis in rapidly dividing cells.

2D構造

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
CC1CN(c2cc3c(cc2F)c(=O)c(C(=O)O)cn3-c2ccc(F)cc2F)CCN1

                

                

                
                

                    
InChI

                    
InChI=1S/C21H18F3N3O3/c1-11-9-26(5-4-25-11)19-8-18-13(7-16(19)24)20(28)14(21(29)30)10-27(18)17-3-2-12(22)6-15(17)23/h2-3,6-8,10-11,25H,4-5,9H2,1H3,(H,29,30)

                

                

                

                    
                    

                        
Molecular Formula

                        
C21H18F3N3O3

                    

                    
                    

                        
HBD / HBA

                        
2 / 9

                    

                    
                    

                        
回転可能結合数

                        
3

                    

                    
                    
                    

                        
重原子数

                        
30

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
よくある質問

                

                    
                    

                        
                        

                            
Temafloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, enzymes essential for DNA replication, transcription, and repair, producing bactericidal effects against a broad spectrum of gram-positive and gram-negative organisms. It was withdrawn from the market in 1992 due to a rare but serious syndrome of hemolytic anemia, hypoglycemia, and coagulopathy (temafloxacin syndrome). Its pharmacological mechanism is similar to other fluoroquinolones but its idiosyncratic toxicity profile led to permanent market withdrawal.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Inhibits DNA topoisomerase, preventing the relaxation of supercoiled DNA during replication and transcription. This causes DNA strand breaks and triggers apoptosis in rapidly dividing cells.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Temafloxacin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL277100.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 60021.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
医学的免責事項

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.